Marcos Rodríguez, Ana Teresa and Navarro-Pando, José Manuel anateresa.marcos@uneatlantico.es, jose.navarro@uneatlantico.es (2020) Letter: cfDNA testing in recurrent pregnancy loss: a new step in the right way but still raw for the clinical area. Human Reproduction, 36 (3). pp. 827-829. ISSN 0268-1161
Full text not available from this repository.Abstract
Sir, In their recently published study, Yaron et al. (2020) expose an interesting strategy based in cfDNA testing (cfDNA-T) which could serve as an alternative to cytogenetic analysis in products of conceptions in recurrent pregnancy loss and could guide further management of this medical topic; however, in our opinion, some important aspects should be considered. Firstly, Illanes et al. (2007) found that cfDNA concentration in the maternal blood can be detected from Week 4 of gestation but it is only reliable from Week 7. However, others authors’ experience could be different. Clark-Ganheart et al. (2015) recommend cfDNA analysis only after 8 weeks of gestation. Zeevi et al. (2018) reported that aneuploidy screening by cfDNA is not generally accurate before Week 8, leading to a period in pregnancy (namely, Weeks 4 through 8) during which assessment of the genetic status of the embryo is not generally feasible. Galeva et al....
| Item Type: | Article |
|---|---|
| Subjects: | Subjects > Biomedicine |
| Divisions: | Europe University of Atlantic > Research > Scientific Production |
| Depositing User: | Sr Bibliotecario |
| Date Deposited: | 08 Feb 2022 11:45 |
| Last Modified: | 30 Jun 2023 10:19 |
| URI: | http://repositorio.funiber.org/id/eprint/510 |
Actions (login required)
 |
View Item |
